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ABSTRACT
Introduction Population ageing and increasing chronic 
illness burden have sparked interest in innovative care 
models. While self- management interventions (SMIs) are 
drawing increasing attention, evidence of their efficacy 
is mostly based on pairwise meta- analysis, generally 
derived from randomised controlled trials comparing 
interventions versus a control or no intervention. As such, 
relevant efficacy data for comparisons among different 
SMIs that can be applied to specific chronic conditions are 
missing. Therefore, the relevance of the available evidence 
for decision- making at clinical, organisational and policy 
levels is limited.
Aim To identify, compare and rank the most effective 
and cost- effective SMIs for adults with four high- priority 
chronic conditions: type 2 diabetes, obesity, chronic 
obstructive pulmonary disease,and heart failure.
Methods and analysis All activities will be conducted 
as part of the cost- effectiveness of self- management 
interventions in four high- priority chronic conditions in 
Europe(COMPAR- EU, Comparing effectiveness of self- 
management interventions in 4 high priority chronic 
diseases inEurope) Project, an European Union (EU)- funded 
project designed to bridge the gap between current 
knowledge and practice on SMIs. In the first phase of the 
project, we will develop and validate a taxonomy, and a 
Core Outcome Set for each condition. These activities will 
inform a series of systematic review and network meta- 
analysis about the effectiveness of SMIs. We will also 
perform a cost- effectiveness analysis of the most effective 
SMIs and an evaluation of contextual factors. We will finally 
develop tailored decision- making tools for the different 
relevant stakeholders.
Ethics and dissemination Ethical approval was obtained 
from the local ethics committee (University Institute for 
Primary Care Research - IDIAP Jordi Gol). All patients 
and other stakeholders will provide informed consent 
prior to participation. This project has been funded by the 
EU Horizon 2020 research and innovation programme 
(grant agreement no. 754936). Results will be of interest 
to relevant stakeholder groups (patients, professionals, 
managers, policymakers and industry), and will be 
disseminated in a tailored multi- pronged approach that 
will include deployment of an interactive platform.
InTRoduCTIon
As population ageing accelerates worldwide, 
chronic illness will place an increasing burden 
on society and healthcare systems.1 Chronic 
conditions affect over 80% of people aged 
over 65 in Europe and account for an esti-
mated 77% of disease burden, as measured 
by disability- adjusted life years.2 Furthermore, 
between 70% and 80% of healthcare costs in 
Europe can be attributed to chronic disease, 
and the current €700 billion expenditure is 
expected to rise.3
Strengths and limitations of this study
 ► The project will result in the largest network meta- 
analysis (NMA) of complex self- management inter-
ventions (SMIs).
 ► SMIs are inconsistently defined across the literature 
potentially generating a high level of heterogeneity 
for the NMA, which we will mitigate by developing a 
validated taxonomy.
 ► The development of Core Outcome Sets with in-
put from patients and other stakeholders for each 
chronic condition will ensure that outcomes as-
sessed in the NMA are relevant to the target users.
 ► The comparative effectiveness analysis via NMA, 
cost- effectiveness and contextual factors evaluation 
will provide new knowledge that should facilitate fu-
ture implementation of successful SMIs.
 ► An interactive platform will facilitate access to 
decision- making tools relevant to the specific needs 
of the different target users.
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Self- management support has become a key strategy for 
addressing chronic disease burden,4 contributing to the 
paradigm shift from a paternalistic model where patients 
are viewed as passive recipients of care, towards more 
equitable and collaborative models of clinician–patient 
interaction.5
Cost- effectiveness of self- management interventions 
in four high- priority chronic conditions in Europe 
(COMPAR- EU) is an EU- funded project designed to 
bridge the gap between current knowledge and prac-
tice on self- management interventions (SMIs). For the 
purpose of this project, we define self- management 
as ‘actions that individuals, families, and communi-
ties engage in to promote, maintain, or restore health 
and cope with illness and disability, with or without the 
support of health professionals, and including but not 
limited to self- prevention, self- diagnosis, self- medication, 
and coping with illness and disability’.6
Self- management of a chronic condition requires 
self- efficacy, largely understood as a person’s confi-
dence in their ability to cope with their illness.7 To be 
self- efficacious, people need special skills to cope with 
the consequences of the disease, including monitoring 
symptoms and clinical markers, understanding the impli-
cations of these, and adjusting behaviours treatment 
accordingly.
SMIs are supportive interventions systematically deliv-
ered or led by healthcare staff or other patients with 
the aim of building patients’ confidence and equip-
ping them with the necessary skills. Their purpose is to 
actively engage patients (and informal caregivers where 
appropriate) in the management of their disease.8 As 
such, they are more than merely didactic, instructional 
programmes, as their primary objective is to bring about 
changes in behaviour and trigger a sequence of positive 
knock- on effects.9
SMIs are complex interventions,9 typically character-
ised by multiple factors (components, formats, settings, 
target behaviours, etc) that interact over time as partic-
ipants move back and forth between the intervention 
processes and everyday life, which can entail challenges in 
measuring effectiveness. Despite this, there is promising 
evidence that SMIs, under given conditions, can improve 
clinical outcomes in numerous chronic conditions, such 
as diabetes (reduction of haemoglobin A1c (HbA1C) 
levels),10 obesity (reduction of weight loss),11 12 chronic 
obstructive pulmonary disease (COPD) (improvement of 
dyspnoea)13 and heart failure (reduction of mortality).14 
SMIs have also been associated with improvements in 
patient- reported outcomes, such as quality of life, and 
more specific disease measures,15 such as self- efficacy16 
and adherence.17
Evidence on the efficacy of SMIs to date has mostly come 
from systematic reviews that have employed pairwise meta- 
analysis of randomised controlled trials (RCTs). System-
atic reviews pool evidence from RCTs comparing the 
same interventions and have long been considered as the 
highest standard in evidence- based healthcare. Pairwise 
meta- analysis, however, leaves a crucial gap, because it 
requires the RCT’s that are pooled to have included the 
same interventions. To provide decision- makers, clini-
cians and patients with solid evidence on how effective 
an SMI is for a given outcome and disease, multiple inter-
ventions need to be compared. In COMPAR- EU, we plan 
to do this using NMA to assess the relative effectiveness of 
SMIs in four chronic conditions.
NMA synthesises direct and indirect evidence across 
a network of multiple interventions. This method has 
numerous advantages: it provides more precise effect 
estimates, allows for the estimation of relative effective-
ness between interventions that have not been compared 
directly and provides a ranking of interventions by 
effectiveness, presenting thus a potential analytical 
advantage.18–22 NMA has been in use for some years, an 
empirical evaluation of 456 NMAs published up to 2015 
showed that just 16% of these addressed complex inter-
ventions23 such as SMIs.24
To support future reimbursement decisions based on 
estimates of the long- term effects of SMIs, we will develop 
simulation models in the four disease areas which will 
translate benefits as identified by the NMA into long- term 
health benefits expressed in quality- adjusted life years 
(QALYs), which enables us to compare not only SMIs 
within but also across the four conditions. The simula-
tion models will also include a cost- effectiveness compo-
nent. Cost- effectiveness analyses are important as they 
help to prioritise health expenditure. There is evidence 
that certain SMIs are cost- effective. Weight reduction 
in obesity, for example, can produce short- term savings 
and increase the chances of remaining in employment,25 
resulting in additional societal gains, while COPD manage-
ment interventions can improve quality of life at generally 
acceptable societal costs,26 and in some cases even result 
in short- term healthcare cost savings.27 Secondary cardio-
vascular risk prevention programmes have the potential 
to reduce direct healthcare expenditure and improve 
health outcomes.28 While these results have not yet been 
structured into a consolidated body of knowledge, they 
do indicate that investing in SMIs may be cost- effective.
A better understanding of facilitators and barriers to 
successful programme implementation is also essential. 
Contextual factors at various levels (patient, patient–
provider interaction, organisation and system) can 
all influence SMI uptake, engagement and success. 
Improving our understanding of how these factors influ-
ence the effectiveness and cost- effectiveness of complex 
SMIs for chronic illness is much needed.
Aim
COMPAR- EU is a multimethod interdisciplinary project 
that will run from 2018 to 2022. The project has been 
designed to help bridge the gap between current knowl-
edge and practice in SMIs for chronic illness. Its aim is 
to identify, compare and rank the most effective SMIs for 
adults living with four high- priority chronic conditions 
(type 2 diabetes, obesity, COPD and heart failure), and 
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Figure 1 COMPAR- EU Phases and main tasks, presents a visual summary of the main phases of the project as described in 
this protocol. COS, Core Outcome Set; NMA, network meta- analysis; RCTs, randomised controlled trials; SMI, self- management 
intervention.
among these interventions, categorise the most cost- 
effective and feasible SMIs. The results of the project 
will facilitate informed decision- making and support 
the implementation of best practices in different health-
care contexts through an interactive platform featuring 
decision- making tools, and other end products for poli-
cymakers, guideline developers, researchers, healthcare 
professionals, patients and industry.
The specific objectives are to (1) validate a taxonomy 
of SMIs; (2) identify and prioritise SMI outcomes from 
the perspective of both patients and practitioners, culmi-
nating in a Core Outcome Set (COS) for each condition; 
(3) carrying out systematic reviews to synthesise existing 
evidence on SMIs from RCTs; (4) compare the relative 
effectiveness of SMIs through NMA; (5) model the cost- 
effectiveness impact of SMIs; (6) analyse contextual 
and implementation factors and (7) develop and pilot 
decision- making tools to facilitate access to and use of the 
most effective SMIs among key target end users.
METhodS And AnAlySIS
The COMPAR- EU project is divided into seven phases 
following to our specific objectives. Each phase is further 
described and shown in figure 1 (COMPAR- EU Phases 
and main tasks).
Phase 1: refinement and validation of a taxonomy of SMIs
Taxonomies are formal systems for classifying multifac-
eted, complex phenomena according to a set of common 
conceptual domains and dimensions; their use increases 
clarity in defining and comparing complex phenomena.29 
Several taxonomies for SMIs have been developed in the 
literature, but so far have focused in a specific area of the 
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intervention (eg, self- management behaviour) and have 
not been validated. In the first phase of COMPAR- EU, we 
will produce a conceptual map and classification system 
that will be evaluated by self- management experts and 
stakeholders (including patients) through a modified 
Delphi technique consisting of a two- round online survey. 
The list of candidate participants will include authors on 
self- management or related topics taxonomies, profes-
sional experts in self- management and patient repre-
sentatives. The resulting feedback and suggestions for 
refinement will be integrated into a new version that will 
be tested by the research team when classifying the SMIs 
reported in the RCTs that will be included in the NMA.
Phase 2: development of core outcome sets for each condition
Interventions can only be compared across studies when 
they share at least some common outcomes, and appro-
priate selection of outcomes is essential if research is to 
guide decision- making and inform policy. We will there-
fore develop a COS for each of the four chronic condi-
tions included in the project.
Outcome catalogue
The first step is to create an exhaustive database listing 
outcomes reported in previous EU projects (PRO- STEP30 
and EMPATHIE31) and COMET, a COS database and 
other relevant organisations (using a snowballing tech-
nique). For each condition, outcomes will be classified into 
different categories, such as clinical outcomes, patient- 
reported outcome measures or resource utilisation.
Systematic review of how patients value self-management 
outcomes
To identify patient priorities for self- management in the 
selected conditions, we will conduct a scoping review, 
of quantitative and qualitative studies, and a series of 
specific overviews for each condition about what patients, 
and their caregivers’ value on SMIs.
Delphi survey with patient representatives
We plan to include patient participation in our outcome 
selection as it has been described as a good practice to 
minimise the influence of power differentials between 
stakeholders.32 We will use a modified Delphi survey 
administered to a convenience sample of patients, and 
patient representatives to ensure that our research 
addresses outcomes that matter to patients (and other 
stakeholders). Four panels of patients and carers, for 
each disease separately (5–8 members) will be given the 
task of prioritising relevant outcomes on a Likert scale.
Consensus workshop
The proposals for each of the four COSs will be presented 
to a panel of patients and other stakeholders (healthcare 
professionals, policymakers and researchers) in a work-
shop that aims to achieve consensus across groups on 
the most important outcomes to include in each COS. 
Participants will be previously provided with the results of 
the patient prioritisation process, and with the results of 
the synthesis of results from the literature review. We will 
establish criteria to address potential discrepancies across 
stakeholders.
Phase 3: systematic review—descriptive synthesis of the 
evidence
Preparations for data collection
We will develop a protocol following Cochrane guid-
ance33 34 and hold training sessions for those respon-
sible for collecting data. Before the extraction process, 
all reviewers will be trained and undergo calibration 
to ensure inter- rater agreement. Additionally, in the 
extraction process, all data collected will be reviewed by 
an independent researcher to ensure quality.
Literature search and screening
To identify relevant RCTs, we will draw on the databases 
of previous European project (PRO- STEP) that identi-
fied hundreds of systematic reviews on SMIs for diabetes, 
obesity, COPD and heart failure. We will use these RCTs 
published from 2000 up to 2015 (last date of SR publi-
cation included in those projects) in our project, and 
update this data set through new searches in MEDLINE, 
CINAHL, Embase, Cochrane and PsycINFO. We will 
include RCTs that compared SMIs in adults with at least 
one of our conditions of interest (type 2 diabetes, obesity, 
COPD or heart failure) and are published in English or 
Spanish. The search will be focused in RCTs published 
from 2015 to 2018 to complement the findings of the SR 
included in PRO- STEP, with the possibility of including 
previous years if the systematic reviews from PRO- STEP 
have not covered those previous years sufficiently. An 
total estimate of 4000 RCTs, based on the results of a 
previous overview,30 will be included for the four priori-
tised chronic conditions.
Data extraction and collection
We will extract data including patient characteristics, 
disease characteristics and comorbidities, intervention 
characteristics (guided by the taxonomy), outcomes 
(guided by the four COSs), results, and information on 
study design and risk of bias. Specific attention will be 
paid to subgroups of patients according to comorbidity, 
gender and socioeconomic variables (eg, health literacy).
Descriptive analysis and summary of SMIs and outcomes
SMIs and outcomes identified in the RCTs will be 
described and summarised to provide information on 
type and number of interventions, outcome results, 
patient characteristics and presence of comorbidities for 
each of the four conditions.
Phase 4: systematic review—nMA and certainty of evidence
Network meta-analysis
We will initially develop theoretical models that make 
explicit the mechanisms through which the different 
SMIs operate on a given outcome. Based on our taxonomy 
of interventions, these models will identify hierar-
chies of elements (type of support provided, expected 
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self- management behaviour, mode of delivery of the 
intervention, provider, etc) that operate on the outcome 
to identify which components or which combinations of 
components are most effective.
Additionally to the standard NMA models, we will 
employ component NMA35–37 to identify key intervention 
components and create a ranking of SMIs according to 
their effectiveness. During this process, it is crucial that 
major assumptions of NMA like transitivity (that there 
must be no relevant discrepancy or inconsistency between 
direct and indirect evidence38) are satisfied, as the validity 
of results will depend on the plausibility of the assump-
tions made. We will also explore the distribution of effect 
modifiers (eg, comorbidities, gender and socioeconomic 
factors) across the various comparisons. This will include 
differentiation, if possible, between the various forms of 
‘usual care’ reported in the included studies.
Evaluation and summary of the certainty of the evidence
To guide users in knowing how much confidence they 
can place in the summarised evidence; we will rate the 
certainty of evidence, obtained through the network 
meta- analysis, for each outcome of interest, using the 
Grading of Recommendations, Assessment, Development 
and Evaluations (GRADE) approach.39–41 Additionally, we 
will apply an alternative approach, the CINeMA frame-
work, to assess the confidence in the results by exploring 
how information flows in the network and how much 
studies at high/unclear risk of bias affect the network 
meta- analysis estimates. We will explore how the assess-
ment differs between these two approaches.
Phase 5: model the cost-effectiveness of effective SMIs
For the cost- effectiveness analysis, data on short- term 
effects on intermediate outcomes (eg, body mass index, 
HbA1C) from the NMA will serve as input for simula-
tion models that extrapolate these effects into long- term 
health effects expressed in QALYs. These health benefits 
will be combined with costs (in 2019 Euro’s) to estimate 
the incremental cost per QALY gained. The development 
of the health economic models will follow a stepped 
approach. First, a conceptual model of the disease will 
be developed, informed by a review of the literature. 
The conceptual model will inform which statistical tech-
niques and models to use (eg, discrete- event models, 
Markov models, patient- level simulation models). 
These decisions will be guided by good practice guide-
lines from pharmacoeconomic communities of medical 
decision- making and the International Society for Phar-
macoeconomics and Outcomes Research42 available data 
and clinical expertise available within the consortium. In 
all four disease models, the natural course of each of the 
four study conditions will be modelled with incorpora-
tion of background events and disease- specific mortality 
and morbidity. Intervention costs will take into account 
societal, healthcare, and patient perspectives, and where 
possible, special attention will be given to societal costs 
that have historically been understudied (eg, productivity 
gains and changes in caregiver burden and costs in life- 
years gained).37 By expressing health benefits in QALYs, 
we will be able to produce a ranking of the most cost- 
effective SMIs, within and across conditions. The base 
cases for the models will have a societal perspective, a 
life- time time horizon, apply differential discounting at 
4% for costs and 1.5% for health (with sensitivity anal-
ysis for equal discounting at 3%). The incremental cost- 
effectiveness ratios will be evaluated against the so- called 
v- threshold that denotes willingness to pay (WTP) for a 
QALY.43 The WTP in the base case is assumed to be the 
median WTP of €24 226, per QALY as found in the system-
atic review on WTP thresholds by Ryen and Svensson,44 
with sensitivity analyses using the mean WTP threshold 
from that same review of € 74,159,44 and country- specific 
thresholds where available. Reporting will include 
scenario analyses to evaluate structural uncertainty as well 
as univariate and probabilistic sensitivity analysis to eval-
uate parameter uncertainty.
Phase 6: analyse the contextual factors that promote 
implementation in real life contexts
For each of the most effective SMIs identified for the 
four chronic conditions, we will perform a realist system-
atic review45 to identify key determinants of success (or 
failure), such as intervention settings (eg, whether on 
a primary care level or hospital level care) and mecha-
nisms (eg, engagement processes) that produce specific 
outcomes. At the patient level, special attention will 
be paid to comorbidities, gender and socioeconomic 
dimensions such as health literacy to better understand 
how these influence the implementation of the selected 
SMIs. We will then use a modified Delphi method, with 
experts on self- management and/or implementation of 
healthcare interventions, to establish the importance of 
these contextual factors in the target countries (Belgium, 
Germany, Greece, the Netherlands and Spain). Experts 
will be asked to rate the magnitude of the influence of a 
contextual factor of a list developed by researchers. The 
final list of the contextual factors will be produced in a 
final expert discussion.
Phase 7: development and piloting of the CoMPAR-Eu 
information technology platform, and preparation for future 
implementation
We will develop an online platform that will integrate 
all the information and evidence synthesised during 
the different phases of the project. The aim is that the 
resources included facilitate decision- making for target 
end users (patients, healthcare professionals, policy-
makers, researchers and small and medium- sized enter-
prises (SMEs)). The platform will include the following 
GRADE- based tools:
 ► Evidence profiles and Interactive Summary of Find-
ings tables46: these presentations will provide informa-
tion in different formats about the quality of evidence, 
and magnitude of relative and absolute effects for 
each of the core outcomes identified.
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Figure 2 COMPAR- EU platform, decision- making tools and other end products, presents a visual summary of the projects’ 
foreseen main products and how they relate to the key stakeholders. COS, Core Outcome Set; NMA, network meta- analysis; 
SMI, self- management intervention.
 ► Evidence to Decision (EtD) frameworks: using semi-
automatic templates, interactive EtD frameworks47 will 
be completed for a number of priority questions that 
will take into account the magnitude of desirable and 
undesirable effects, stakeholder views on the impor-
tance of different outcomes, information on resource 
use and cost- effectiveness, impact on equity, and other 
aspects like acceptability or feasibility of the interven-
tions. The frameworks will include draft recommen-
dations that could be then applied or adapted to 
different settings.
 ► Patient decision aids: will be developed in plain- 
language for all selected situations identified in 
the previous phases of the study. The aids will be 
produced in six languages (English, French, German, 
Spanish, Dutch and Greek) and will include informa-
tion obtained in some of the phases included in the 
project.
Development of COMPAR-EU online platform
The COMPAR- EU online platform will feature structured 
interfaces tailored to the needs of different end users. It 
will be designed so that after answering a few simple ques-
tions, users will be guided to the tool or product that best 
suits their needs (figure 2 illustrates the main products to 
be integrated into the platform and expected end- users).
Piloting and refinement of decision-making tools with different 
stakeholders
The COMPAR- EU platform will be piloted to gauge poten-
tial barriers to its implementation and understand how to 
position the decision- making tools in the target health-
care markets. Decision aids will be piloted among patients 
and health professionals and EtD frameworks and other 
products will be piloted with other stakeholders (eg, poli-
cymakers, industry and representatives of patient associa-
tions) that may be involved in implementing the tools in 
the five participating countries. Piloting will be organised 
in focus groups and user experience tests in simulated 
settings using techniques such as thinking- out- loud. Pilots 
with patient associations and clinicians will focus on the 
actual use of the decision aids, where pilots with industry 
and policymakers will focus on the potential reimburse-
ment and integration into existing IT tools. Results of the 
piloting will be used to further improve the tools.
Preparation of future implementation
Even with well- developed and user- friendly decision tools, 
integration in existing policy and regulatory frameworks 
is crucial for successful uptake of our recommendations. 
Using expert networks, we will assess the grey literature, 
current guidelines and legislation to identify and analyse 
relevant policy and regulatory frameworks and stan-
dards on patient participation, health technology assess-
ment agencies, eHealth/mHealth and other topics that 
might influence the uptake of the self- management and 
decision- making tools designed within COMPAR- EU. 
The purpose is to ensure that current legislative, regu-
latory and reimbursement decisions at EU level are 
appropriately considered in exploiting the results of the 
COMPAR- EU project. We will also hold workshops with 
industry, pharma and SMEs to identify business oppor-
tunities resulting from the research findings that could 
result in long- term sustainable dissemination.
PATIEnT And PuBlIC InvolvEMEnT
Patients are a key component of the COMPAR- EU project 
from start to finish and their interests are represented by 
the European Patient Forum (EPF), which is one of the 
consortium partners. Together with other stakeholders, 
they will be involved in different aspects of the project 
including prioritisation of core outcomes and testing of 
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interactive tools. A core group of partners, led by the EPF, 
will also be created to ensure co- production and establish-
ment of explicit criteria to incorporate patient views into 
project outcomes, products and communication inter-
ventions. Plain- language material will also be developed 
to support the main end products of the project.
EThICS And dISSEMInATIon
The project coordinator (Avedis Donabedian Research 
Institute) requested the overall ethical approval for the 
project to our local Clinical Research Ethics Committee 
(CEIC) (the University Institute for Primary Care 
Research—IDIAP Jordi Gol). Ethical approval was 
granted on March 2018. Results are of interest to several 
stakeholder groups (patients, professionals, managers, 
policymakers and industry) and will be disseminated 
in a tailored multi- pronged approach, including the 
creation of an interactive platform. The data generated 
by the project will be managed following the Golden 
Open access as defined by the European Commission for 
Horizon 2020 research projects.48
dATA ShARIng STATEMEnT
COMPAR- EU project will make all its anonymised data 
available on reasonable request, where required this will 
be at aggregated level. The main data dictionaries and 
databases generated by the project will be available on 
requests for uses related to research and quality improve-
ment, and potentially for commercial exploitation, subject 
to approval by the consortium. Data availability and access 
is governed by the COMPAR- EU Data Management Plan 
which is aligned with the EU Open Data Initiative and 
the FAIR Principles.49 Further details and information on 
how to access the data will be available from COMPAR- 
EU’s project website (https:// self- management. eu/).
PATIEnT And PuBlIC InvolvEMEnT
EPF, a key umbrella organisation in patient representa-
tion and European level is a partner of this project and 
as such has contributed to the project from its inception 
and design.
Furthermore, we have planned for patient participa-
tion in key stages of the project, including the selection 
of outcomes for the Core Outcome Sets, advise towards 
patient end products and participating in the design 
and piloting of the COMPAR- EU platform and related 
decision- making tools.
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